Anonymous
Guest
Anonymous
Guest
On a more serious note, I would point to three things that I saw:
1. Failure to effectively negotiate w/FDA to get a label for Galvus. They were willing to allow B.I.D dosing but we pushed for QD and were rejected. The drug is selling millions in Europe. We expanded FF's in anticipation and have been dealing with fallout ever since. I think this was the biggest blunder.
2. Launching Elidel without an indication for under 2 years of age. Anybody that knows eczema knows that most usage is in the first 2 years. We were asking for trouble. Lawsuits are mounting on this. It never made sense to me.
3. Being caught off guard and losing the Lotrel patent. I was in a room when Alex Gorsky said "We now have a team devoted to patent protection that will report directly to me". NOW? We did not do a pay-for-delay, as in the case of Diovan. This was clearly a blunder.
All the personnel stuff happens in every company. Believe me, its no different anywhere else.
It's always easy to spot someone 'in the know' here on cp.
Well Said! Well Spoken!